Quest Diagnostics Incorporated ($DGX) Stock Forecast: Down 1.0% Today

What is Quest Diagnostics Incorporated?

Quest Diagnostics (DGX) is a leading provider of diagnostic testing, information, and services, offering insights to improve health. The company operates a network of laboratories and patient service centers.

Why is Quest Diagnostics Incorporated going down?

DGX stock is down 1.0% on Feb 2, 2026 15:43

• The bearish movement in Quest Diagnostics (DGX) stock today could be attributed to several factors:
• The launch of a new ultrasensitive blood test for measurable residual disease (MRD) in multiple myeloma patients by Quest Diagnostics may have raised concerns about potential competition in the diagnostic testing market, impacting investor sentiment.
• The significant increase in stake by AlphaQuest LLC in Quest Diagnostics, coupled with company insiders selling off stock, might have led to uncertainty among investors about the company's future performance.
• Despite receiving a "Moderate Buy" consensus rating from analysts and positive price target revisions, the overall market sentiment towards Quest Diagnostics may have been overshadowed by the news of new product launches and insider selling activities.

DGX Price Chart

DGX Technical Analysis

DGX News

New myeloma blood test offers alternative to painful bone marrow biopsies

Quest Diagnostics has launched a new ultrasensitive blood test, Quest Flow Cytometry MRD for Myeloma, which aims to improve the detection and monitoring of measurable residual disease (MRD) in multiple myeloma patients. This test offers sensitivity comparable to next-generation sequencing but at a lower cost and uses non-invasive blood samples, providing an alternative to painful bone marrow biopsies. The new test also boasts a five-day specimen stability, making it more accessible for nationwide testing, and can be used without a pre-treatment baseline aspirate.

https://www.stocktitan.net/news/DGX/quest-diagnostics-launches-novel-flow-cytometry-mrd-blood-test-for-v9w8imthp0d4.html

Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

Quest Diagnostics has launched a new ultrasensitive blood test for measurable residual disease (MRD) in multiple myeloma patients, using advanced flow cytometry. The "Quest Flow Cytometry MRD for Myeloma" test offers sensitivity comparable to next-generation sequencing but at a lower cost and with five-day specimen stability, supporting wider access despite requiring bone marrow aspirate. This innovation enhances disease monitoring and is expected to be useful for clinical trials evaluating new treatments for myeloma.

https://www.streetinsider.com/PRNewswire/Quest+Diagnostics+Launches+Novel+Flow+Cytometry+MRD+Blood+Test+for+Myeloma%2C+Enabling+Ultrasensitive+Detection+of+Residual+Disease/25928028.html

Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor

Hans Vestberg, former Chairman and CEO of Verizon, has joined Digi Power X Inc. as a senior advisor to support the company's expansion strategy. Vestberg brings extensive experience in telecommunications and infrastructure, which will be invaluable as Digipower X focuses on deploying AI-ready modular data centers to address bottlenecks in power availability, cooling capacity, and deployment speed for AI adoption. The company aims to provide Tier-3 modular AI data centers within approximately 180 days, leveraging its vertically integrated power strategy and energy assets.

https://finance.yahoo.com/news/hans-vestberg-former-verizon-chairman-123000215.html

AlphaQuest LLC Acquires 6,284 Shares of Quest Diagnostics Incorporated $DGX

AlphaQuest LLC significantly increased its stake in Quest Diagnostics (NYSE:DGX) by 3,396.8% in Q3, purchasing 6,284 shares to now own a total of 6,469 shares valued at approximately $1.23 million. While institutional investors have been buying, company insiders, including CEO J.E. Davis, have been net sellers of Quest Diagnostics stock. The company recently announced a quarterly dividend of $0.80, representing an annualized dividend of $3.20 and a 1.7% yield.

https://www.marketbeat.com/instant-alerts/filing-alphaquest-llc-acquires-6284-shares-of-quest-diagnostics-incorporated-dgx-2026-02-02/

Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Rating of "Moderate Buy" from Analysts

Quest Diagnostics (NYSE:DGX) has received a "Moderate Buy" consensus rating from 16 research firms, with eight analysts issuing a buy rating and eight issuing a hold rating. The average 1-year price target set by these brokerages is $198.27, with some firms like Barclays and Jefferies recently raising their targets. The article also highlights the company's financial performance, dividend announcement, insider transactions, and institutional investor activity.

https://www.marketbeat.com/instant-alerts/quest-diagnostics-incorporated-nysedgx-receives-consensus-rating-of-moderate-buy-from-analysts-2026-02-02/

Trending Today

Coty Inc. Class A ($COTY) Stock Forecast: Up 5.0% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.0% Today

Interactive Brokers Group, Inc. ($IBKR) Stock Forecast: Up 3.8% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 5.4% Today

Carvana Co ($CVNA) Stock Forecast: Up 5.3% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 7.5% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.1% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Up 5.1% Today

IDEXX Laboratories Inc. ($IDXX) Stock Forecast: Down 1.7% Today

Silver ($XAG) Commodity Forecast: Down 5.4% Today

Quest Diagnostics Incorporated Price History

02.09.2025 - DGX Stock was down 5.0%

• Today, despite collaborations with Epic and Rutgers Cancer Institute, DGX encountered a downward movement.
• Speculations suggest the market response could be influenced by overall market trends, sector shifts, or profit collection by traders.
• Some investors might have been anticipating swift financial gains from the partnerships, potentially triggering a temporary stock sell-off.
• Observing the progress of these collaborations is crucial to evaluate their influence on DGX's financial results and stock valuation.

21.09.2025 - DGX Stock was down 2.7%

• Despite surpassing Q3 earnings and revenue estimates, Quest Diagnostics (DGX) experienced a bearish movement in the market today.
• The market might have reacted negatively due to profit-taking by investors after the recent positive performance.
• Investors may have been expecting even higher results, leading to a sell-off post-earnings announcement.
• The stock's strong bearish movement could also be influenced by broader market conditions or sector-specific factors impacting healthcare companies.

02.01.2026 - DGX Stock was down 1.0%

• The bearish movement in Quest Diagnostics (DGX) stock today could be attributed to several factors:
• The launch of a new ultrasensitive blood test for measurable residual disease (MRD) in multiple myeloma patients by Quest Diagnostics may have raised concerns about potential competition in the diagnostic testing market, impacting investor sentiment.
• The significant increase in stake by AlphaQuest LLC in Quest Diagnostics, coupled with company insiders selling off stock, might have led to uncertainty among investors about the company's future performance.
• Despite receiving a "Moderate Buy" consensus rating from analysts and positive price target revisions, the overall market sentiment towards Quest Diagnostics may have been overshadowed by the news of new product launches and insider selling activities.

19.02.2025 - DGX Stock was down 5.1%

• Quest Diagnostics (DGX) experienced a bearish movement today.
• Aveanna (AVAH) surging 6.2% might have diverted investor attention away from DGX.
• The lack of positive earnings estimate revisions for Aveanna could have prompted investors to move funds out of DGX and into more promising opportunities.
• The shift in focus towards Aveanna's potential gains may have contributed to the bearish movement in Quest Diagnostics (DGX) today.

23.06.2025 - DGX Stock was down 0.6%

• Despite surpassing Q2 earnings and revenue estimates, Quest Diagnostics (DGX) witnessed a bearish market movement.
• The market potentially reacted negatively due to profit-taking by investors following a 3.2% rise in pre-market trading post the positive earnings results.
• Investors might have anticipated higher numbers or future guidance, leading to a sell-off after the earnings announcement.
• The robust historical performance of Quest Diagnostics possibly elevated expectations to a level where meeting estimates was insufficient to maintain the bullish momentum, resulting in today's bearish movement.

22.06.2025 - DGX Stock was up 5.2%

• Over the past 5 years, Quest Diagnostics (DGX) has delivered impressive performance, surpassing the market with an average annual return of 508.21%.
• The positive market movement of Quest Diagnostics is possibly influenced by expectations of beating earnings estimates in the upcoming report.
• Investor sentiment towards Quest Diagnostics remains upbeat due to its solid historical performance and growth potential in the diagnostic testing sector.

21.04.2025 - DGX Stock was down 5.1%

• Today's decline in DGX's stock price could be linked to profit-taking by investors following the recent surge.
• The market reaction might be influenced by broader economic conditions or specific news affecting the healthcare sector, resulting in a temporary downturn for DGX.
• Investors may be reevaluating their positions in DGX after the recent uptrend, causing a short-term decrease in the stock price.

22.03.2025 - DGX Stock was up 7.7%

• Quest Diagnostics (DGX) stock showed a strong bullish movement.
• The company surpassed expectations with its first quarter 2025 earnings and revenues, outperforming analyst projections.
• The stock's upward trend can be attributed to the favorable earnings report and sustained growth over the past 5 years.
• Investor optimism in Quest Diagnostics' performance and market position is likely driving the stock price increase.

22.03.2025 - DGX Stock was up 5.8%

• Strong Q1 earnings and revenues exceeded expectations, signaling robust financial performance and potentially favorable future outlook.
• Over the last 5 years, the stock has consistently outperformed the market, demonstrating steady growth and investor trust.
• Although there was a minor decline in stock price in the past month, the significant rise over the last year indicates sustained positive momentum.
• Anticipated earnings growth is reinforcing the bullish trend, implying ongoing profitability and investor confidence in the company's prospects.

22.03.2025 - DGX Stock was up 8.2%

• Quest Diagnostics (DGX) experienced a robust upward movement today.
• The company exceeded earnings expectations for the first quarter, resulting in a notable surge in its stock price.
• Over the past 5 years, Quest Diagnostics has consistently outperformed, showcasing an impressive average annual return that has likely boosted investor confidence and interest in the stock.
• Strong earnings and revenue results for the quarter ending in March 2025 indicate a solid performance by the company, potentially fueling additional investor confidence and driving the stock price upwards.

22.06.2025 - DGX Stock was up 6.0%

• Quest Diagnostics (DGX) exceeded Q2 earnings and revenue estimates, showcasing a 15.2% revenue growth and a significant EPS beat, leading to a 3.2% rise in the stock price.
• The company's consistent outperformance over the past 5 years, with an impressive annualized return of 508.21%, has likely contributed to investor confidence and positive market sentiment.
• With a history of surpassing earnings expectations and favorable market conditions, Quest Diagnostics (DGX) appears well-positioned to continue its upward trajectory, attracting further investor interest and driving the bullish movement in the stock price.

01.09.2025 - DGX Stock was down 3.7%

• The partnership between DGX's Haystack Oncology and Rutgers Cancer Institute to study the application of ctDNA MRD test in guiding therapy for lung cancer could have raised concerns about the company's current testing methods or future revenue streams.
• Investors might be worried about the potential impact on DGX's market share or competitive position in the oncology diagnostic testing space.
• The market might be reacting to the uncertainty surrounding the outcome of the study and its implications for DGX's future growth prospects in the oncology segment.